David Apelian - Jul 3, 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role
CEO, Director
Signature
/s/ David Apelian
Stock symbol
EIGR
Transactions as of
Jul 3, 2023
Transactions value $
$0
Form type
4
Date filed
7/6/2023, 05:37 PM
Previous filing
Feb 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +750K $0.00 750K Jul 3, 2023 Common Stock 750K $0.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in equal monthly installments over 48 months measured from July 3, 2023, subject to the Reporting Person's continuous service as of each such date.